6; 95% CI, 0.19-0.69)
and increased primary
patency when venous
grafts were analyzed
separately (OR, 0.44; 95%
CI, 0.14-1.42). Bleeding
risk doubled compared
with antiplatelets
At 6 months
postintervention,
reocclusion was lower
with high-dose ASA Ã¾
dipyrid